{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.3","upperLimit":"54.6","value":"41.4"},{"groupId":"OG001","lowerLimit":"24.4","upperLimit":"62.7","value":"41.0"},{"groupId":"OG002","lowerLimit":"18.1","upperLimit":"57.0","value":"44.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"description":"Topotecan plasma concentration-time data are collected on day 1 of maintenance cycle A1 after a single oral dose. Individual estimates of topotecan apparent oral clearance are obtained using post hoc analysis.","dispersionType":"Full Range","groups":[{"description":"Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma","id":"OG000","title":"Low-Risk Group"},{"description":"Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease","id":"OG001","title":"Intermediate-Risk Group"},{"description":"Patients with central nervous system (CNS) metastatic disease","id":"OG002","title":"High-Risk Group"}],"paramType":"MEDIAN","populationDescription":"Eligible patients who received oral topotecan during maintenance therapy cycle A1 and had samples collected for PK analysis.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0.25, 1.5 and 6 hours post-dose","title":"Topotecan Apparent Oral Clearance in Maintenance Chemotherapy","type":"SECONDARY","unitOfMeasure":"L/h"}